IBDEI16S ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20176,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,20176,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,20177,0)
 ;;=C92.02^^84^929^6
 ;;^UTILITY(U,$J,358.3,20177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20177,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,20177,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,20177,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,20178,0)
 ;;=D09.3^^84^929^45
 ;;^UTILITY(U,$J,358.3,20178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20178,1,3,0)
 ;;=3^Carcinoma in Situ of Thyroid/Oth Endocrine Glands
 ;;^UTILITY(U,$J,358.3,20178,1,4,0)
 ;;=4^D09.3
 ;;^UTILITY(U,$J,358.3,20178,2)
 ;;=^5001955
 ;;^UTILITY(U,$J,358.3,20179,0)
 ;;=C22.0^^84^929^86
 ;;^UTILITY(U,$J,358.3,20179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20179,1,3,0)
 ;;=3^Hepatocellular Carcinoma
 ;;^UTILITY(U,$J,358.3,20179,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,20179,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,20180,0)
 ;;=C24.9^^84^929^110
 ;;^UTILITY(U,$J,358.3,20180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20180,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,20180,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,20180,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,20181,0)
 ;;=C50.922^^84^929^134
 ;;^UTILITY(U,$J,358.3,20181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20181,1,3,0)
 ;;=3^Malig Neop Left Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,20181,1,4,0)
 ;;=4^C50.922
 ;;^UTILITY(U,$J,358.3,20181,2)
 ;;=^5133340
 ;;^UTILITY(U,$J,358.3,20182,0)
 ;;=C34.91^^84^929^152
 ;;^UTILITY(U,$J,358.3,20182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20182,1,3,0)
 ;;=3^Malig Neop Right Bronchus/Lung,Unspec Part
 ;;^UTILITY(U,$J,358.3,20182,1,4,0)
 ;;=4^C34.91
 ;;^UTILITY(U,$J,358.3,20182,2)
 ;;=^5000967
 ;;^UTILITY(U,$J,358.3,20183,0)
 ;;=C50.921^^84^929^156
 ;;^UTILITY(U,$J,358.3,20183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20183,1,3,0)
 ;;=3^Malig Neop Right Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,20183,1,4,0)
 ;;=4^C50.921
 ;;^UTILITY(U,$J,358.3,20183,2)
 ;;=^5001198
 ;;^UTILITY(U,$J,358.3,20184,0)
 ;;=C90.02^^84^929^167
 ;;^UTILITY(U,$J,358.3,20184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20184,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,20184,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,20184,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,20185,0)
 ;;=D51.9^^84^929^25
 ;;^UTILITY(U,$J,358.3,20185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20185,1,3,0)
 ;;=3^Anemia in Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,20185,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,20185,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,20186,0)
 ;;=C79.51^^84^929^30
 ;;^UTILITY(U,$J,358.3,20186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20186,1,3,0)
 ;;=3^Bone Mets
 ;;^UTILITY(U,$J,358.3,20186,1,4,0)
 ;;=4^C79.51
 ;;^UTILITY(U,$J,358.3,20186,2)
 ;;=^5001350
 ;;^UTILITY(U,$J,358.3,20187,0)
 ;;=C80.1^^84^929^163
 ;;^UTILITY(U,$J,358.3,20187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20187,1,3,0)
 ;;=3^Malig Neop,Primary,Unspec Site
 ;;^UTILITY(U,$J,358.3,20187,1,4,0)
 ;;=4^C80.1
 ;;^UTILITY(U,$J,358.3,20187,2)
 ;;=^5001389
 ;;^UTILITY(U,$J,358.3,20188,0)
 ;;=C80.0^^84^929^164
 ;;^UTILITY(U,$J,358.3,20188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20188,1,3,0)
 ;;=3^Malig Neop,Unspec Primary or Secondary
 ;;^UTILITY(U,$J,358.3,20188,1,4,0)
 ;;=4^C80.0
 ;;^UTILITY(U,$J,358.3,20188,2)
 ;;=^5001388
 ;;^UTILITY(U,$J,358.3,20189,0)
 ;;=Z85.818^^84^930^92
 ;;^UTILITY(U,$J,358.3,20189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20189,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lip,Oral Cavity & Pharynx
